327 related articles for article (PubMed ID: 29271696)
1. Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model.
Liu C; Chu X; Sun P; Feng X; Huang W; Liu H; Ma Y
Hum Vaccin Immunother; 2018 Apr; 14(4):931-940. PubMed ID: 29271696
[TBL] [Abstract][Full Text] [Related]
2. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
4. Chimeric HBcAg virus-like particles presenting a HPV 16 E7 epitope significantly suppressed tumor progression through preventive or therapeutic immunization in a TC-1-grafted mouse model.
Chu X; Li Y; Long Q; Xia Y; Yao Y; Sun W; Huang W; Yang X; Liu C; Ma Y
Int J Nanomedicine; 2016; 11():2417-29. PubMed ID: 27313455
[TBL] [Abstract][Full Text] [Related]
5. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
Yang Y; Che Y; Zhao Y; Wang X
Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
[TBL] [Abstract][Full Text] [Related]
6. Self-Assembled Nanofibers Elicit Potent HPV16 E7-Specific Cellular Immunity And Abolish Established TC-1 Graft Tumor.
Li S; Zhang Q; Bai H; Huang W; Shu C; Ye C; Sun W; Ma Y
Int J Nanomedicine; 2019; 14():8209-8219. PubMed ID: 31632028
[TBL] [Abstract][Full Text] [Related]
7. Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant.
Korsholm KS; Hansen J; Karlsen K; Filskov J; Mikkelsen M; Lindenstrøm T; Schmidt ST; Andersen P; Christensen D
Vaccine; 2014 Jun; 32(31):3927-35. PubMed ID: 24877765
[TBL] [Abstract][Full Text] [Related]
8. Enhanced anti-tumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150.
Chen S; Ou R; Tang J; Deng X; Wu Y; van Velkinburgh JC; Ni B; Xu Y
Cancer Epidemiol; 2013 Apr; 37(2):172-8. PubMed ID: 23127963
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
[TBL] [Abstract][Full Text] [Related]
10. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
11. Heterologous administration of HPV16 E7 epitope-loaded nanocomplexes inhibits tumor growth in mouse model.
Goradel NH; Negahdari B; Mohajel N; Malekshahi ZV; Shirazi MMA; Arashkia A
Int Immunopharmacol; 2021 Dec; 101(Pt B):108298. PubMed ID: 34739928
[TBL] [Abstract][Full Text] [Related]
12. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
[TBL] [Abstract][Full Text] [Related]
13. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin.
Mansilla C; Berraondo P; Durantez M; Martínez M; Casares N; Arribillaga L; Rudilla F; Fioravanti J; Lozano T; Villanueva L; Sarobe P; Borrás F; Leclerc C; Prieto J; Lasarte JJ
Int J Cancer; 2012 Aug; 131(3):641-51. PubMed ID: 21898393
[TBL] [Abstract][Full Text] [Related]
14. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
15. Engineered outer membrane vesicle is potent to elicit HPV16E7-specific cellular immunity in a mouse model of TC-1 graft tumor.
Wang S; Huang W; Li K; Yao Y; Yang X; Bai H; Sun W; Liu C; Ma Y
Int J Nanomedicine; 2017; 12():6813-6825. PubMed ID: 28979120
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model.
Ishida E; Lee J; Campbell JS; Chakravarty PD; Katori Y; Ogawa T; Johnson L; Mukhopadhyay A; Faquin WC; Lin DT; Wirth LJ; Pierce RH; Pai SI
Cancer Immunol Immunother; 2019 Aug; 68(8):1273-1286. PubMed ID: 31243491
[TBL] [Abstract][Full Text] [Related]
17. CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice.
Hansen J; Lindenstrøm T; Lindberg-Levin J; Aagaard C; Andersen P; Agger EM
Cancer Immunol Immunother; 2012 Jun; 61(6):893-903. PubMed ID: 22095092
[TBL] [Abstract][Full Text] [Related]
18. Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.
Varypataki EM; van der Maaden K; Bouwstra J; Ossendorp F; Jiskoot W
AAPS J; 2015 Jan; 17(1):216-26. PubMed ID: 25387996
[TBL] [Abstract][Full Text] [Related]
19. A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity.
Song YC; Cheng HY; Leng CH; Chiang SK; Lin CW; Chong P; Huang MH; Liu SJ
J Control Release; 2014 Jan; 173():158-65. PubMed ID: 24177312
[TBL] [Abstract][Full Text] [Related]
20. Immuno-Stimulating Peptide Derived from HMGB1 is More Effective Than the N-Terminal Domain of Gp96 as an Endogenous Adjuvant for Improvement of Protein Vaccines.
Talebi S; Bolhassani A; Azad TM; Arashkia A; Modaresi MH
Protein Pept Lett; 2017; 24(3):190-196. PubMed ID: 28000571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
